年龄对非小细胞肺癌患者免疫治疗结局的影响
该回顾性研究纳入2013年1月至2017年7月启动PD-1/PD-L1抑制剂治疗的245例NSCLC患者,按年龄分组比较疗效与毒性。各年龄组中位PFS差异未达统计学显著(log-rank P=0.055),中位OS差异有统计学意义(log-rank P=0.011),免疫相关毒性、激素使用及住院率在各年龄组间无差异。
要点
- 各年龄组中位PFS差异未达统计学显著(log-rank P=0.055)。
- 各年龄组中位OS差异有统计学意义(log-rank P=0.011)。
- 免疫相关毒性、激素使用及住院率在各年龄组间无差异。
核心结论
- 免疫治疗的OS和PFS获益因年龄而异,但毒性发生率在各年龄组相似。
研究设计与样本
- 回顾性评估2013年1月至2017年7月启动PD-1/PD-L1抑制剂治疗的NSCLC患者,共245例。
- 按年龄分组:<60岁占26.1%,60-69岁占31.4%,70-79岁占31.0%,≥80岁占11.4%。
- 查阅病历和影像学资料以确定PFS和OS,并按年龄比较免疫相关毒性、激素使用及住院情况。
主要发现
- 中位PFS:<60岁1.81个月,60-69岁2.53个月,70-79岁3.75个月,≥80岁1.64个月(log-rank P=0.055)。
- 中位OS:<60岁13.01个月,60-69岁14.56个月,70-79岁12.92个月,≥80岁3.62个月(log-rank P=0.011)。
- 免疫相关毒性、激素使用及住院率在各年龄组间无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immunotherapy has revolutionized the treatment of NSCLC, but little is known about the activity of programmed cell death 1 and programmed death ligand 1 blockade across age groups. METHODS: We retrospectively evaluated patients with NSCLC who initiated programmed cell death 1 and programmed death ligand 1 inhibitors from January 2013 through July 2017. Medical records and radiographic imaging were reviewed to determine progression-free survival (PFS) and overall survival (OS). We also compared immunotherapy-related toxicities, steroid use, and hospitalizations by age. RESULTS: Of the 245 patients, 26.1% were younger than 60 years, 31.4% were age 60 to 69 years, 31.0% were age 70 to 79 years, and 11.4% were age 80 years or older. The median PFS times by age group were as follows: younger than 60 years, 1.81 months; age 60 to 69 years, 2.53 months; age 70 to 79 years, 3.75 months; and age 80 years or older, 1.64 months (log-rank p value = 0.055). The median OS times by age group were as follows: younger than 60 years, 13.01 months; age 60 to 69 years, 14.56 months; age 70 to 79 years, 12.92 months; and age 80 years or older, 3.62 months (log-rank p value = 0.011). Rates of immunotherapy-related toxicities, steroid use, and hospitalizations did not differ by age. CONCLUSIONS: Although the OS and PFS benefits of immunotherapy differ by age, the rates of toxicity are similar regardless of age.
引用
- Lichtenstein MRL, Nipp RD, Muzikansky A, et al. Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 30476576. doi:10.1016/j.jtho.2018.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。